Greten Tim F, Manns Michael P, Korangy Firouzeh
Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Germany, Carl Neuberg Str. 1, 30625 Hannover, Germany.
Rev Recent Clin Trials. 2008 Jan;3(1):31-9. doi: 10.2174/157488708783330549.
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide with increasing incidence in the Western World. In contrast to most other malignancies, only surgical and local ablative therapeutic options have shown efficacy in patients with HCC. Systemic chemotherapy has failed to show a substantial benefit for these patients. Therefore, a number of immunotherapeutic trials have been performed to evaluate the efficacy of immunotherapy for the treatment of HCC. Although only a limited number of patients have been enrolled in most trials so far, results from these studies clearly suggest that immunotherapy is safe in HCC patients. Here, we review recent immunotherapy trials in HCC.
肝细胞癌（HCC）是全球第五大常见癌症，在西方世界发病率呈上升趋势。与大多数其他恶性肿瘤不同，只有手术和局部消融治疗方案在HCC患者中显示出疗效。全身化疗未能对这些患者显示出实质性益处。因此，已经进行了一些免疫治疗试验来评估免疫疗法治疗HCC的疗效。尽管到目前为止大多数试验仅纳入了有限数量的患者，但这些研究结果清楚地表明免疫疗法对HCC患者是安全的。在此，我们综述了近期HCC免疫治疗试验。
